ISRCTN56242729 https://doi.org/10.1186/ISRCTN56242729

Assessment of the value of hyoscine butylbromide (Buscopan®) in optimising image quality for patients undergoing pelvic magnetic resonance imaging

Submission date
30/09/2004

Recruitment status
No longer recruiting

Registration date
30/09/2004

Overall study status
Completed

Last Edited
05/04/2012

Condition category
Other

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr B Taylor

Contact details
X-Ray Diagnostic
Christie Hospital NHS Trust
Wimslow Road
Withington
Manchester
United Kingdom
M20 4BX

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0063139427

Study information

Scientific Title

Study objectives
To determine whether intravenous hyoscine butylbromide (Buscopan®) results in a significant improvement in magnetic resonance (MR) image quality and improves diagnostic accuracy, thereby benefitting patients.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
A cohort observation, randomised single-blinded trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Screening

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Magnetic resonance imaging (MRI)

Interventions
Before pelvic magnetic resonance imaging patient will received either intravenous hyoscine butylbromide or a placebo.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Hyoscine butylbromide (Buscopan®)

Primary outcome measure
Overall image quality and visualisation of individual pelvic structures and visualisation of tumours on MR images, both with and without Buscopan®.

Secondary outcome measures
Not provided at time of registration

Overall study start date
20/01/2004

Completion date
31/12/2008

Eligibility

Key inclusion criteria
Patients undergoing pelvic magnetic resonance imaging.

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
20/01/2004

Date of final enrolment
31/12/2008

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
X-Ray Diagnostic
Manchester
United Kingdom
M20 4BX

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Government

Funder Name
Christie Hospital NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2007		Yes	No